171 related articles for article (PubMed ID: 36091125)
1. Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy.
Zhao N; Yi Y; Cao W; Fu X; Mei N; Li C
Front Oncol; 2022; 12():923531. PubMed ID: 36091125
[TBL] [Abstract][Full Text] [Related]
2. Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels.
Zhao N; Jiang A; Shang X; Zhao F; Wang R; Fu X; Ruan Z; Liang X; Tian T; Yao Y; Li C
J Immunother; 2023 Oct; 46(8):310-322. PubMed ID: 37335173
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy.
Wang H; Zhou F; Zhao C; Cheng L; Zhou C; Qiao M; Li X; Chen X
Front Immunol; 2022; 13():840313. PubMed ID: 35222434
[TBL] [Abstract][Full Text] [Related]
4. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
Front Immunol; 2022; 13():987568. PubMed ID: 36159840
[TBL] [Abstract][Full Text] [Related]
5. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
Tyan K; Baginska J; Brainard M; Giobbie-Hurder A; Severgnini M; Manos M; Haq R; Buchbinder EI; Ott PA; Hodi FS; Rahma OE
Cancer Immunol Immunother; 2021 Aug; 70(8):2209-2221. PubMed ID: 33481042
[TBL] [Abstract][Full Text] [Related]
6. Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments.
Shi Y; Liu X; Liu J; Zhang D; Liu X; Yue Y; Zhou Q; Gao X; Chen M; Xu Y; Zhao J; Zhong W; Provencio M; Jassem J; Williams TM; Seeber A; Kocher F; Wang M
Transl Lung Cancer Res; 2021 Dec; 10(12):4477-4493. PubMed ID: 35070755
[TBL] [Abstract][Full Text] [Related]
7. Changes of IL-6 And IFN-γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study.
Zhang X; Lu X; Yu Y; Tan K; Cui H
Medicine (Baltimore); 2022 Nov; 101(46):e31761. PubMed ID: 36401365
[TBL] [Abstract][Full Text] [Related]
8. Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: a retrospective cohort study.
Zhang K; Zhou C; Gao J; Yu P; Lin X; Xie X; Liu M; Zhang J; Xie Z; Cui F; Li S; Passiglia F; Stella GM; Qin Y
Transl Lung Cancer Res; 2022 Nov; 11(11):2306-2317. PubMed ID: 36519030
[TBL] [Abstract][Full Text] [Related]
9. Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis.
Wang D; Chen C; Gu Y; Lu W; Zhan P; Liu H; Lv T; Song Y; Zhang F
Front Oncol; 2021; 11():631949. PubMed ID: 33732650
[TBL] [Abstract][Full Text] [Related]
10. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
11. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
12. Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence.
Xu H; Feng H; Zhang W; Wei F; Zhou L; Liu L; Zhao Y; Lv Y; Shi X; Zhang J; Ren X
Exp Cell Res; 2022 Jul; 416(1):113157. PubMed ID: 35427598
[TBL] [Abstract][Full Text] [Related]
13. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
14. Association between increased peripheral blood CD86-positive plasmacytoid dendritic cells and immune-related adverse events in patients with non-small cell lung cancer.
Karayama M; Mizoguchi Y; Inoue Y; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suda T; Kitano S; Aoki K; Yamada Y
Glob Health Med; 2022 Dec; 4(6):301-308. PubMed ID: 36589213
[TBL] [Abstract][Full Text] [Related]
15. Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Miao K; Zhang X; Wang H; Si X; Ni J; Zhong W; Zhao J; Xu Y; Chen M; Pan R; Wang M; Zhang L
Front Immunol; 2022; 13():912180. PubMed ID: 35844502
[TBL] [Abstract][Full Text] [Related]
16. Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients.
Gérard A; Doyen J; Cremoni M; Bailly L; Zorzi K; Ruetsch-Chelli C; Brglez V; Picard-Gauci A; Troin L; Esnault VLM; Passeron T; Montaudié H; Seitz-Polski B
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088741
[TBL] [Abstract][Full Text] [Related]
17. Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Sonehara K; Tateishi K; Araki T; Komatsu M; Akahane J; Yamamoto H; Hanaoka M
Cancer Manag Res; 2022; 14():427-435. PubMed ID: 35140520
[TBL] [Abstract][Full Text] [Related]
18. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
20. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
